SCI Abstract

search
+
Cadonilimab is effective and safe in recurrent cervical cancer
The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy ...
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress
Author notesThese authors contributed equally: Shelley A. Jazowski, Rahul K. Nayak.Authors and AffiliationsDepartment of H...
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, includi...
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?
A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appeti...
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic horm...
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes
Approximately 40% of hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancers harbour activating mutations in...
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, ...
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Over the past few years, several novel systemic treatments have emerged for patients with treatment-refractory metastatic ...
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of the...
BrECADD raises the bar in classical Hodgkin lymphoma
The eBEACOPP regimen, consisting of bleomycin, vincristine, procarbazine and prednisone plus escalated doses of etoposide,...
Tisotumab vedotin effective in recurrent cervical cancer
Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited trea...
HER2-targeted therapies beyond breast cancer — an update
HER2-targeted therapies beyond breast cancer — an update
The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic target in patients with breast o...
Spatial landscapes of cancers: insights and opportunities
Spatial landscapes of cancers: insights and opportunities
Solid tumours comprise many different cell types organized in spatially structured arrangements, with substantial intratum...
Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC
Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-...
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Authors and AffiliationsDivision of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Ita...
Blinatumomab improves outcomes in adult MRD-negative BCP-ALL
Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after ind...
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas
The efficacy of chimeric antigen receptor (CAR) T cell therapy for solid tumours has been disappointing to date. However, ...
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges
A recent study reported the development and validation of the Liver Artificial Intelligence Diagnosis System (LiAIDS), a f...
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Patients with recurrent, platinum-sensitive epithelial ovarian cancer (defined as disease relapse ≥6 months after first-li...
Global epidemiology of epithelial ovarian cancer
Global epidemiology of epithelial ovarian cancer
Globally, ovarian cancer is the eighth most common cancer in women, accounting for an estimated 3.7% of cases and 4.7% of ...
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Patients with locally advanced cervical cancer usually receive chemoradiotherapy (CRT) as first-line therapy, although thi...
Nucleic acid-based drugs for patients with solid tumours
Nucleic acid-based drugs for patients with solid tumours
The treatment of patients with advanced-stage solid tumours typically involves a multimodality approach (including surgery...
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Antiangiogenic agents, generally antibodies or tyrosine-kinase inhibitors that target the VEGF–VEGFR pathway, are cu...
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. Howe...
Patients with uncommon EGFR mutations also benefit from first-line osimertinib
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of pat...
Personalizing adjuvant therapy for patients with colorectal cancer
Personalizing adjuvant therapy for patients with colorectal cancer
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrim...
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the cur...
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or...
From the ESMO Congress 2023
As in 2017, this year’s ESMO Congress brought many members of the oncology community together in Madrid, this time with &g...
Load More
format_indent_increase